Pfizer closed at $23.72 in the latest trading session after falling 2.47%, a drop that left the stock behind a market that moved higher across the board. The S&P 500 gained 0.72%, the Dow rose 0.3% and the Nasdaq increased 1.12% as Pfizer slipped.
The move matters now because the stock has already lost 6.61% over the last month, while the Medical sector gained 12.48% and the S&P 500 fell 0.9% in the same stretch. For shareholders, that means Pfizer is not just trailing the broad market for one day. It is also lagging a sector that has been gaining ground.
Investors are watching the name closely because Pfizer is slated to report earnings on August 4, 2026. The company is projected to post $0.68 per share, which would be a 12.82% decline from a year earlier, while revenue is expected to reach $14.48 billion, down 1.2% from the corresponding quarter last year. That estimate picture has not been static: the Zacks Consensus EPS estimate moved 0.03% lower over the last 30 days.
The valuation gap is another reason the stock keeps showing up on screens. Pfizer’s Forward P/E ratio is 8.15, versus 16.26 for the industry. Put another way, Pfizer is trading at about half the multiple of the Large Cap Pharmaceuticals industry, a discount of roughly 49.8% based on those figures. Yet the market has not rewarded that gap in the latest session, and the stock’s decline came even as the broader indexes advanced.
Pfizer carries a Zacks Rank of #3, Hold, which sits in the middle of a system that runs from #1, Strong Buy, to #5, Strong Sell. The next earnings report on August 4 will likely bring the clearest read yet on whether the recent estimate drift and the stock’s weak trading are pointing to a deeper problem or just a stretch of hesitation before results.
